Ellis, Anne K.
Cook, Victoria
Keith, Paul K.
Mace, Sean R.
Moote, William
O’Keefe, Andrew
Quirt, Jaclyn
Rosenfield, Lana
Small, Peter
Watson, Wade
Article History
Received: 23 August 2023
Accepted: 21 May 2024
First Online: 8 August 2024
Declarations
:
: Not applicable.
: Not applicable.
: A.K. Ellis has participated in advisory boards for ALK-Abello, AstraZeneca, Bausch Health, LEO Pharma, Miravo, Merck, Novartis, has been a speaker for ALK-Abello, AstraZeneca, Bausch, Miravo, Medexus, Mylan, Novartis, Pfizer, Sanofi, StallergenesGreer and Regeneron. Her institution has received research grants from ALK Abello, Aralez, AstraZeneca, Bayer LLC, Medexus, Novartis, Sanofi and Regeneron. She has also served as an independent consultant to Bayer LLC, Pharming, and Regeneron. V. Cook has received honoraria for speaking engagements for Miravo/Aralez, Pfizer, and ALK and served on advisory boards or speakers’ bureaus for Sanofi and ALK. P. Keith Paul has participated in advisory boards for ALK-Abello, AstraZeneca, Bausch Health, CSL Behring, GlaxoSmithKline, LEO Pharma, Miravo, Merck, Novartis, Sanofi, Takeda and Valeo. He has been a speaker for ALK-Abello, Bausch, GlaxoSmithKline, Medexus, Novartis, and Sanofi. His institution has received research grants from CSL Behring and Takeda. He has also served as a consultant to Bayer LLC, CADTH, and the Canadian Pharmacists Association. S.R. Mace has served on a speakers’ bureau for Miravo. W. Moote has nothing to disclose. A. O’Keefe reports research funding from Sanofi, has served as a speaker for Novartis, ALK, Innomar, Medexus, GlaxoSmithKline, Sanofi, and has served as a consultant for ALK, Sanofi, Takeda and Astra Zeneca. J. Quirt has participated in advisory boards for Aralez and Sanofi. L. Rosenfield has nothing to disclose. P. Small has nothing to disclose. W. Watson has nothing to disclose.
: All recommendations in this document are evidence based and concluded on by all authors equally as consensus-based recommendations.